Epigenomic alterations in localized and advanced prostate cancer

Neoplasia (United States)

Volumn 15, Issue 4, 2013, Pages 373-383

  Lin, Pei Chun ^a   Giannopoulou, Eugenia G ^a   Park, Kyung ^a   Mosquera, Juan Miguel ^a   Sboner, Andrea ^a   Tewari, Ashutosh K ^a   Garraway, Levi A ^b,c   Beltran, Himisha ^a   Rubin, Mark A ^a   Elemento, Olivier ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY GROWTH RESPONSE FACTOR; FILAMIN A; GLUTATHIONE TRANSFERASE; SHAW POTASSIUM CHANNEL; TROPOMYOSIN;

ADULT; AGED; ALLELE; ARTICLE; BENIGN TUMOR; CASTRATION RESISTANT PROSTATE CANCER; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DISEASE COURSE; DISEASE SEVERITY; DNA METHYLATION; EPIGENETICS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84875675666     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.122146     Document Type: Article

References (48)

1. Bray F, Jemal A, Grey N, Ferlay J, and Forman D (2012). Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol 13, 790-801.
2. Siegel R, Naishadham D, and Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin 62, 10-29.
3. Prensner JR, Rubin MA, Wei JT, and Chinnaiyan AM (2012). Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 4, 127rv123.
4. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, et al. (2012). Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367, 203-213.
5. Bernstein BE, Meissner A, and Lander ES (2007). The mammalian epigenome. Cell 128, 669-681.
6. Nelson WG, De Marzo AM, and Yegnasubramanian S (2009). Epigenetic alterations in human prostate cancers. Endocrinology 150, 3991-4002.
7. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM, Brooks JD, Myers RM, and Sherlock G (2011). DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 21, 1017-1027.
8. Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, Klee GG, Tindall DJ, and Donkena KV (2012). Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 18, 2882-2895.
9. Kron K, Pethe V, Briollais L, Sadikovic B, OzcelikH, Sunderji A, Venkateswaran V, Pinthus J, Fleshner N, van der Kwast T, et al. (2009). Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One 4, e4830.
10. Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S, Huang C, Shankar S, Jing X, Iyer M, et al. (2011). Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res 21, 1028-1041.
11. Borno ST, Fischer A, Kerick M, Falth M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, et al. (2012). Genome-wide DNA methylation events in TMPRSS2:ERG fusion negative prostate cancers implicate an EZH2 dependent mechanism with miRNA-26a hypermethylation. Cancer Discov 2(11), 1024-1035.
12. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, IsaacsWB, and NelsonWG (2004). Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64, 1975-1986.
13. Bedford MT and van Helden PD (1987). Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res 47, 5274-5276.
14. Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, et al. (2008). DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 68, 8954-8967.
15. Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann MM, et al. (2012). Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res 72, 616-625.
16. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, et al. (2011). Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 1, 487-495.
17. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, et al. (2011). The genomic complexity of primary human prostate cancer. Nature 470, 214-220.
18. Akalin A, Garrett-Bakelman FE, Kormaksson M, Busuttil J, Zhang L, Khrebtukova I, Milne TA, Huang Y, Biswas D, Hess JL, et al. (2012). Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet 8, e1002781.
19. Reik W and Walter J (2001). Genomic imprinting: parental influence on the genome. Nat Rev Genet 2, 21-32.
20. Kerkel K, Spadola A, Yuan E, Kosek J, Jiang L, Hod E, Li K, Murty VV, Schupf N, Vilain E, et al. (2008). Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet 40, 904-908.
21. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, Cantor CR, Field JK, and van den Boom D (2005). Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA 102, 15785-15790.
22. Krueger F and Andrews SR (2011). Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 27, 1571-1572.
23. Giannopoulou EG and Elemento O (2011). An integrated ChIP-seq analysis platform with customizable workflows. BMC Bioinformatics 12, 277.
24. Elemento O, Slonim N, and Tavazoie S (2007). A universal framework for regulatory element discovery across all genomes and data types. Mol Cell 28, 337-350.
25. Goodarzi H, Elemento O, and Tavazoie S (2009). Revealing global regulatory perturbations across human cancers. Mol Cell 36, 900-911.
26. Gertz J, Varley KE, Reddy TE, Bowling KM, Pauli F, Parker SL, Kucera KS, Willard HF, and Myers RM (2011). Analysis of DNA methylation in a threegeneration family reveals widespread genetic influence on epigenetic regulation. PLoS Genet 7, e1002228.
27. Breiman L (2001). Random forests. Mach Learn 45, 5-32.
28. Ku M, Koche RP, Rheinbay E, Mendenhall EM, Endoh M, Mikkelsen TS, Presser A, Nusbaum C, Xie X, Chi AS, et al. (2008). Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet 4, e1000242.
29. Gal-Yam EN, Egger G, Iniguez L, Holster H, Einarsson S, Zhang X, Lin JC, Liang G, Jones PA, and Tanay A (2008). Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci USA 105, 12979-12984.
30. Statham AL, Robinson MD, Song JZ, Coolen MW, Stirzaker C, and Clark SJ (2012). Bisulfite sequencing of chromatin immunoprecipitatedDNA (BisChIP-seq) directly informs methylation status of histone-modified DNA. Genome Res 22, 1120-1127.
31. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E, Reubinoff BE, et al. (2007). Polycombmediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39, 232-236.
32. Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM, and Elemento O (2010). EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 116, 5247-5255.
33. Kubosaki A, Tomaru Y, Tagami M, Arner E, Miura H, Suzuki T, Suzuki M, Suzuki H, and Hayashizaki Y (2009). Genome-wide investigation of in vivo EGR-1 binding sites in monocytic differentiation. Genome Biol 10, R41.
34. Watari A, Takaki K, Higashiyama S, Li Y, Satomi Y, Takao T, Tanemura A, Yamaguchi Y, Katayama I, Shimakage M, et al. (2006). Suppression of tumorigenicity, but not anchorage independence, of human cancer cells by new candidate tumor suppressor gene CapG. Oncogene 25, 7373-7380.
35. Van den Abbeele A, De Corte V, Van Impe K, Bruyneel E, Boucherie C, Bracke M, Vandekerckhove J, and Gettemans J (2007). Downregulation of gelsolin family proteins counteracts cancer cell invasion in vitro. Cancer Lett 255, 57-70.
36. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, Brezillon S, Tyldesley R, Blanpain C, Detheux M, et al. (2003). Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 198, 977-985.
37. Li DQ, Wang L, Fei F, Hou YF, Luo JM, Zeng R, Wu J, Lu JS, Di GH, Ou ZL, et al. (2006). Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 6, 3352-3368.
38. Lomnytska MI, Becker S, Bodin I, Olsson A, Hellman K, Hellstrom AC, Mints M, Hellman U, Auer G, and Andersson S (2011). Differential expression of ANXA6, HSP27, PRDX2, NCF2, and TPM4 during uterine cervix carcinogenesis: diagnostic and prognostic value. Br J Cancer 104, 110-119.
39. Wang L, Darling J, Zhang JS, Liu W, Qian J, Bostwick D, Hartmann L, Jenkins R, Bardenhauer W, Schutte J, et al. (2000). Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma. Genes Chromosomes Cancer 27, 1-10.
40. Burton ER, Gaffar A, Lee SJ, Adeshuko F, Whitney KD, Chung JY, Hewitt SM, Huang GS, Goldberg GL, Libutti SK, et al. (2011). Downregulation of Filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer. Mol Cancer Res 9, 1126-1138.
41. Suzuki MM and Bird A (2008). DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 9, 465-476.
42. Ball MP, Li JB, Gao Y, Lee JH, LeProust EM, Park IH, Xie B, Daley GQ, and Church GM (2009). Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 27, 361-368.
43. Caterino M, Ruoppolo M, Fulcoli G, Huynth T, Orru S, Baldini A, and Salvatore F (2009). Transcription factor TBX1 overexpression induces downregulation of proteins involved in retinoic acid metabolism: a comparative proteomic analysis. J Proteome Res 8, 1515-1526.
44. Ryckebusch L, Bertrand N, Mesbah K, Bajolle F, Niederreither K, Kelly RG, and Zaffran S (2010). Decreased levels of embryonic retinoic acid synthesis accelerate recovery from arterial growth delay in a mouse model of DiGeorge syndrome. Circ Res 106, 686-694.
45. Touma SE, Perner S, Rubin MA, Nanus DM, and Gudas LJ (2009). Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model. Biochem Pharmacol 78, 1127-1138.
46. Kim H, Lapointe J, Kaygusuz G, Ong DE, Li C, van de Rijn M, Brooks JD, and Pollack JR (2005). The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. Cancer Res 65, 8118-8124.
47. Rubin MA, Maher CA, and Chinnaiyan AM (2011). Common gene rearrangements in prostate cancer. J Clin Oncol 29, 3659-3668.
48. Harris RA, Wang T, Coarfa C, Nagarajan RP, Hong C, Downey SL, Johnson BE, Fouse SD, Delaney A, Zhao Y, et al. (2010). Comparison of sequencingbased methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat Biotechnol 28, 1097-1105.